Diabetic Foot Ulcers - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Diabetic Foot Ulcers - Pipeline Review, H2 2016

Diabetic Foot Ulcers - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Diabetic Foot Ulcers - Pipeline Review, H2 2016
Published Nov 23, 2016
157 pages — Published Nov 23, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Foot Ulcers Pipeline Review, H2 2016, provides an overview of the Diabetic Foot Ulcers (Metabolic Disorders) pipeline landscape.

Diabetic foot ulcers are sores that occur on the feet of people with Type 1 Diabetes and Type 2 Diabetes. Symptoms include sores, ulcers, or blisters on the foot or lower leg, pain, walking with difficulty, discoloration in feet: black, blue, or red, cold feet and fever, skin redness or swelling, or other signs of infection. The predisposing factors include diabetic neuropathy, peripheral vascular disease, a foot deformity and history of tobacco use disorder.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Foot Ulcers Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Diabetic Foot Ulcers (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Foot Ulcers (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Foot Ulcers and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 3, 16, 5, 16, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.Diabetic Foot Ulcers.

Diabetic Foot Ulcers (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Foot Ulcers (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Diabetic Foot Ulcers (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diabetic Foot Ulcers (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diabetic Foot Ulcers (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The

  
Source:
Document ID
GMDHC8696IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents28
  List of Tables81
  List of Figures91
Introduction101
  Global Markets Direct Report Coverage101
Diabetic Foot Ulcers Overview111
Therapeutics Development122
  Pipeline Products for Diabetic Foot Ulcers Overview121
  Pipeline Products for Diabetic Foot Ulcers Comparative Analysis131
Diabetic Foot Ulcers Therapeutics under Development by Companies142
Diabetic Foot Ulcers Therapeutics under Investigation by Universities/Institutes161
Diabetic Foot Ulcers Pipeline Products Glance174
  Late Stage Products171
  Clinical Stage Products181
  Early Stage Products191
  Unknown Stage Products201
Diabetic Foot Ulcers Products under Development by Companies213
Diabetic Foot Ulcers Products under Investigation by Universities/Institutes241
Diabetic Foot Ulcers Companies Involved in Therapeutics Development2528
  ANP Technologies Inc251
  CardioVascular BioTherapeutics Inc261
  Celgene Corp271
  Chrysalis BioTherapeutics Inc281
  CytoTools AG291
  EyeGene Inc301
  FirstString Research Inc311
  Genentech Inc321
  GlaxoSmithKline Plc331
  Human Stem Cells Institute341
  Izun Pharmaceuticals Corp351
  Karyopharm Therapeutics Inc361
  Lakewood-Amedex Inc371
  Lytix Biopharma AS381
  Mallinckrodt Plc391
  MediWound Ltd401
  NovaLead Pharma Pvt Ltd411
  Oneness Biotech Co Ltd421
  Osiris Therapeutics Inc431
  Pherecydes Pharma SA441
  Plurogen Therapeutics Inc451
  TechnoPhage SA461
  TGV-Laboratories471
  Theravasc Inc481
  Topadur Pharma AG491
  USV Pvt Ltd501
  viDA Therapeutics Inc511
  ViroMed Co Ltd521
Diabetic Foot Ulcers Therapeutics Assessment539
  Assessment by Monotherapy Products531
  Assessment by Target542
  Assessment by Mechanism of Action562
  Assessment by Route of Administration582
  Assessment by Molecule Type602
Drug Profiles6280
  3K3A-APC Drug Profile622
  ALLO-ASC Drug Profile641
  ANP-017 Drug Profile651
  AP-102 Drug Profile661
  APO-2 Drug Profile671
  becaplermin biosimilar Drug Profile681
  Cell Therapy to Activate Cathelicidin for Diabetic Foot Ulcers and Crural Ulcer Drug Profile692
  Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers Drug Profile711
  CL-05 Drug Profile723
  CODA-001 Drug Profile752
  CVBT-141B Drug Profile771
  Cyndacel-M Drug Profile781
  daprodustat Drug Profile792
  EG-Decorin Drug Profile811
  epidermal growth factor biosimilar Drug Profile821
  EscharEx Drug Profile832
  esmolol hydrochloride Drug Profile851
  Gene Therapy to Activate HIF-1 Alpha for Wound and Ulcers Drug Profile861
  Granexin Drug Profile872
  Heberprot-P Drug Profile891
  IMSP-001 Drug Profile901
  IZN-6D4 Drug Profile911
  LTX-109 Drug Profile922
  MT-003 Drug Profile941
  Mul-1867 Drug Profile951
  Neovasculgen Drug Profile961
  Nu-2 Drug Profile971
  Nu-3 Drug Profile982
  ON-101 Drug Profile1002
  OTI-1501 Drug Profile1021
  PDA-002 Drug Profile1031
  PluroGel N Drug Profile1041
  PP-2351 Drug Profile1051
  Recombinant Protein for Wounds, Bone Regeneration and Diabetic Ulcers Drug Profile1061
  RG-7880 Drug Profile1071
  rusalatide acetate Drug Profile1083
  selinexor Drug Profile11119
  sodium nitrite SR Drug Profile1302
  Stathmin-1 Drug Profile1321
  TOPN-53 Drug Profile1331
  TP-102 Drug Profile1341
  V-10 Drug Profile1351
  VM-202 Drug Profile1364
  VTI-1000 Series Drug Profile1401
  VTI-3000 Series Drug Profile1411
Diabetic Foot Ulcers Dormant Projects1424
Diabetic Foot Ulcers Discontinued Products1461
Diabetic Foot Ulcers Product Development Milestones1479
  Featured News &Press Releases1471
    Aug 24, 2016: MediWound's EscharEx to be Featured at International Society for Burn Injuries 20161471
    Jul 19, 2016: The New Drugs ON101 (WH-1) of Oneness Biotech Meet the Phase III Clinical Trials Interim Requirement and is going to initiate Phase III Clinical Trials in China and EU1471
    Jul 19, 2016: The New Drugs ON101 (WH-1) of Oneness Biotech Successively Pass the Blind Test1471
    Jul 18, 2016: The Oneness Biotech Announce the Phase III Clinical Trials Results1481
    Jul 18, 2016: The Worlds Best New Drugs Healing Rate of Oneness Biotech Is Accelerating Product Launch1481
    Feb 02, 2016: MediWound EscharEx Meets Primary Endpoint in Second Phase 2 Clinical Trial for the Debridement of Chronic and Hard-to-Heal Wounds1482
    Jan 05, 2016: Izun Pharmaceuticals to Present at Biotech Showcase 20161501
    Oct 13, 2015: Izun Pharmaceuticals Announces Positive Results from Phase 2 Randomized Trial in Diabetic Foot Ulcers1501
    Oct 06, 2015: Osiris Announces Initiation of a Phase III Trial for a New Investigational Drug, OTI-15-01, for the Treatment of Chronic Diabetic Foot Wounds1511
    Sep 01, 2015: US FDA Approves Initiation of ViroMed's VM202 for Phase III Clinical Study of Chronic Non-Healing Ischemic Diabetic Foot Ulcer1521
    Jul 31, 2015: Oneness Biotechs Investigational New Drug ON101 for Treating Chronic Diabetic Foot Ulcers Approved for SBIR grant program by Ministry of Economy Affairs1531
    Apr 21, 2015: SCRA Technology Ventures Company Shares Phase 2 Results1541
    Apr 15, 2015: CytoTools: Recruitment Of Patients Now Complete For European Studies On Diabetic Foot And Ulcus Cruris Indications1541
    Jan 22, 2015: Oneness Biotech s Investigational New Drug ON101 Approved for Clinical Pharmacokinetic Studies by Ministry of Health and Welfare1551
    Dec 03, 2014: Oneness Biotech s New Drug ON101 for Treatment of Chronic Diabetic Foot Ulcers Approved for Phase III Human Clinical Trials by Hong Kong Department of Health1551
Appendix1562
  Methodology1561
  Coverage1561
  Secondary Research1561
  Primary Research1561
  Expert Panel Validation1561
  Contact Us1561
  Disclaimer1571

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Diabetic Foot Ulcers - Pipeline Review, H2 2016" Nov 23, 2016. Alacra Store. Apr 25, 2024. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Diabetic-Foot-Ulcers-Pipeline-Review-H2-2016-2088-16871>
  
APA:
Global Markets Direct - Market Research. (2016). Diabetic Foot Ulcers - Pipeline Review, H2 2016 Nov 23, 2016. New York, NY: Alacra Store. Retrieved Apr 25, 2024 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Diabetic-Foot-Ulcers-Pipeline-Review-H2-2016-2088-16871>
  
US$ 2,000.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.